$VITR #Vitrolife AB Vitrolife - Weaker Q2, and tough months still ahead: Q2: organic decline of -45%, EBITDA -24% vs ABGSCe H2’20 will still be impacted by lower demand ‘21e EV/EBIT c.46x on our pre-Q2 estimates https://t.co/G1HLktqStb #equity #stocks https://t.co/6hRwkXzqrp